MedTrace Logo

Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.

NCT05891743 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2024-11-01

No results posted yet for this study

Summary

The goal of this observational study it to learn about the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. The main question it aims to answer is:

\- What is the prevalence of skin sensitization and dermatitis among workers in the wind turbine industry who are exposed to epoxy?

Participants will be asked to perform Patch Test, which is considered the Gold Standard test for identifying the cause of occupational contact allergic dermatitis.

Researchers will compare the results of the epoxy-exposed group with those of a control group comprising non-exposed workers from the same industry. This analysis will help determine if there is a higher prevalence of skin sensitization among workers exposed to epoxy.

Conditions

  • Dermatitis

Interventions

DIAGNOSTIC_TEST

Patch Test

The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.

Sponsors & Collaborators

  • Association for Innovation and Biomedical Research on Light and Image

    collaborator OTHER

  • Siemens Gamesa Renewable Energy Blades, S.A.

    lead INDUSTRY

Principal Investigators

  • Vítor Pinheiro, MD · AIBILI-CEC (AIBILI- Clinical Trials Centre)

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-08
Primary Completion
2024-10-16
Completion
2024-10-16

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891743 on ClinicalTrials.gov